{"altmetric_id":3205344,"counts":{"readers":{"mendeley":1,"citeulike":0,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:88164"],"posts_count":1}},"citation":{"abstract":"To assess the efficacy and safety, and determine the optimal dosage, of a once-daily (OD) formulation of the clinically uroselective alpha(1)-blocker, alfuzosin, in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia.","abstract_source":"pubmed","altmetric_jid":"4f6fa5153cf058f6100036e4","authors":["C G Roehrborn"],"first_seen_on":"2015-01-31T17:08:28+00:00","handles":[],"isbns":[],"issns":["1527-9995"],"issue":"6","journal":"Urology","last_mentioned_on":1250101101,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11744466"],"pmid":"11744466","pubdate":"2001-12-01T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"title":"Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.","type":"article","volume":"58","mendeley_url":"http:\/\/www.mendeley.com\/research\/efficacy-safety-oncedaily-alfuzosin-treatment-lower-urinary-tract-symptoms-clinical-benign-prostatic"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":3622323,"mean":4.9312868762118,"rank":816079,"this_scored_higher_than_pct":63,"this_scored_higher_than":2282653,"rank_type":"exact","sample_size":3622323,"percentile":63},"similar_age_3m":{"total_number_of_other_articles":93729,"mean":7.329155120723,"rank":23986,"this_scored_higher_than_pct":73,"this_scored_higher_than":68652,"rank_type":"exact","sample_size":93729,"percentile":73},"this_journal":{"total_number_of_other_articles":1209,"mean":2.4654238410596,"rank":169,"this_scored_higher_than_pct":64,"this_scored_higher_than":785,"rank_type":"exact","sample_size":1209,"percentile":64},"similar_age_this_journal_3m":{"total_number_of_other_articles":37,"mean":2.7375,"rank":3,"this_scored_higher_than_pct":91,"this_scored_higher_than":34,"rank_type":"exact","sample_size":37,"percentile":91}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Bachelor":1},"by_discipline":{"Agricultural and Biological Sciences":1}}}},"posts":{"wikipedia":[{"title":"Benign prostatic hyperplasia","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=307598493#altmetric_citation_14","license":"public","citation_ids":[3205343,3205344],"posted_on":"2009-08-12T18:18:21+00:00","summary":"Benign prostatic hyperplasia (BPH), also called benign enlargement of the prostate (BEP), adenofibromyomatous hyperplasia and benign prostatic hypertrophy (technically incorrect usage), is a benign increase in size of the prostate.","page_url":"http:\/\/en.wikipedia.org\/?curid=88164","wiki_lang":"en","author":{"name":"Draeco","url":"http:\/\/en.wikipedia.org\/wiki\/User:Draeco"}}]}}